Handok has appointed Kim Mi-yeon as its new president, effective July 1, 2023.

Kim is a leader in the healthcare sector who has achieved remarkable results in the pharmaceutical and medical device industries and has extensive experience in business and strategic planning, brand marketing, drug pricing and reimbursement, organizational management, and customer experience. She is highly skilled in analyzing the rapidly changing healthcare market to formulate business strategies and execution plans, and in collaborative leadership with diverse stakeholders to deliver results.

Kim began her career at Pfizer Korea as a strategic planning manager, brand manager, and marketing manager before heading the Established Product (EP) business unit. She then served as Vice President of the EP Business Unit at Pfizer’s headquarters in the United States, overseeing brands in the States. Since then, she has served as Head of Cardiovascular Metabolic Disease Business at Novartis Korea, President of Alcon Korea, and most recently as CEO of Genuone Sciences, an integrated company of Kolmar Korea’s Pharmaceuticals Business Unit and Kolmar Pharma, where she led the establishment of mid- and long-term business strategies and strengthened sustainability management.

Ms. Kim holds a BA in English Literature from Yonsei University, an MA in Communication from the University of Michigan, and an MBA from Yale University.